Carlos Jiménez-Cortegana
Cristina Poveda2
Gabriel Cabrera- 1Department of Medical Biochemistry, Molecular Biology and Immunology, Faculty of Medicine, University of Seville, Seville, Spain
- 2Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States
- 3Laboratorio de Tecnología Inmunológica, Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe Capital, Argentina
Editorial on the Research Topic
The regulatory immune system as a target to improve adjuvants and novel vaccines
The immune system has evolved innate and adaptive effector mechanisms to target pathogens and abnormal cells. In parallel, diverse immunoregulatory networks are necessary to control the priming, development, and resolution of responses, preventing unnecessary damage to healthy tissues (Banchereau and Steinman, 1998; Belkaid, 2007; Sakaguchi et al., 2020). Therefore, a complex interplay between effector and regulatory components is responsible for the outcome of almost any process involving the immune system. Infections, autoimmune diseases, cancer, and many other settings depend on the critical balance between both arms of the immune system (Sakaguchi et al., 2008; Gabrilovich and Nagaraj, 2009; Pawelec et al., 2019). Vaccination is not an exception (Montes de Oca et al., 2016; Cabrera and Marcipar, 2019; Batista-Duharte et al., 2022). Although vaccines against pathogens and cancer specifically focus on the stimulation of effector mechanisms, immunoregulatory populations may control and limit the magnitude of the response (Fernández et al., 2014; Batista-Duharte et al., 2018). In many cases, only targeting the effector response has allowed the development of successful vaccines (Plotkin, 2010). In other conditions, however, this approach seems insufficient since most attempts to develop vaccines against cancer and several complex pathogens continue failing after decades of research. Human immunodeficiency virus, Staphylococcus aureus, Trypanosoma cruzi, and Candida albicans are only some examples of viruses, bacteria, parasites, and fungi that remain as important pathogens for which a licensed vaccine is not yet available (Plotkin, 2018). Additionally, treating many types of cancer could benefit from developing therapeutic vaccines, but despite extensive research, this possibility is uncommon in clinical practice.
The significant role played by Foxp3+ T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in scenarios where many vaccines have failed, such as cancer and complex infections, highlights the potential benefits of targeting the regulatory arm of the immune system to enhance vaccines that initially only considered the effector response. To support research in this field, this Research Topic has compiled original articles and reviews focused on evasion/subversion strategies and studying the role of immunoregulatory populations during rational vaccine design against complex pathogens or cancer cells.
Compiled reports from the literature provide evidence supporting the notion that MDSCs may play a significant role in many immunization protocols (Prochetto et al.). A timeline of the history of MDSCs in vaccination was elaborated, and the data provided support the involvement of MDSCs in immunization in a manner that is not restricted to a particular pathogen, adjuvant, or immunization route (Prochetto et al.). It was shown that vaccines against viruses, bacteria, parasites, and fungi could cause significant increases in MDSCs that affect the immune response and the protective capacity elicited by diverse immunization protocols. In this sense, subcutaneous, intramuscular, intradermal, and intrarectal immunization routes resulted in the expansion of MDSCs. Similarly, immunostimulating complexes (ISCOMs), Toll-like receptors-agonists, and complete Freund adjuvant were also shown to expand this immunosuppressive population.
Batista-Duharte et al. evaluated the role of Tregs in the efficacy of a recombinant enolase-based vaccine against the Sporothrix brasiliensis fungus. DEREG mice were used to generate a transient depletion of Tregs by diphtheria toxin administration. Results showed that immunization plus Treg depletion caused a significant increase in humoral and cellular parameters compared to immunization without depleting Tregs. The increase in the effector response observed in immunized and Treg-depleted mice correlated with protective capacity against in vivo challenge with S. brasiliensis, supporting the notion that Tregs play a role in limiting the prophylactic immune response elicited by the enolase-based vaccine.
Chulanetra and Chaicumpa reviewed and categorized the mechanisms employed by several human parasites to evade the immune system, including induction of Tregs and regulatory B cells, manipulation of dendritic cells and B cells, antigenic variation, complement evasion, and many others. A deeper understanding of these strategies and the specific molecules used by parasites to cope with the effector and regulatory immune system could be critical to optimizing therapeutic approaches and designing better vaccine candidates.
Regarding cancer, it is widely known the key role that DCs play as antigen-presenting cells in the cancer-immunity cycle (Chen and Mellman, 2013), and their inhibition may promote chronic inflammation (Liu et al., 2021) and a variety of diseases, such as cancer (Del Prete et al., 2023). DC functions are impaired by factors that are found within the tumor microenvironment, including MDSCs (Yang et al., 2020), whose proliferation and expansion have been demonstrated in different types of cancer, including (but not limited to) breast (Sánchez-León et al., 2023), prostate (Koinis et al., 2021), colorectal (Sieminska and Baran, 2020) and ovarian (Mabuchi et al., 2021) cancers, non-Hodgkin lymphoma (Jiménez-Cortegana et al., 2021b) or leukemia (Liu et al., 2017). In recent years, one of the most important areas of research in immuno-oncology has been MDSC targeting. In this sense, MDSCs have shown to be successfully depleted in murine models and cancer patients using conventional treatments such as radiotherapy (Jiménez-Cortegana et al., 2022) or chemotherapy (Palazón-Carrión et al., 2021), as well as immunotherapy (Lu et al., 2017; Jiménez-Cortegana et al., 2021a).
Considering the crucial role of DCs in antitumor immunity, Sánchez-León et al. compiled a set of studies encompassing the effects of DC-based vaccines on the MDSC compartment in both murine models and clinical patients. Although the efficacy of DC vaccination as a monotherapy is still limited compared to other treatments to achieve strong immune responses, these types of vaccines are considered a promising approach because its combination with different types of drugs (e.g., chemotherapeutics or immunomodulatory agents) may synergically boost the effects of the vaccination to overcome MDSC-mediated immunosuppression and, consequently, delay tumor growth and enhance outcomes and survival rates in cancer-bearing mice and oncological patients.
This Research Topic critically discusses the role of immunoregulatory cells during rational vaccine design against pathogens and cancer cells, which may interest researchers who can initiate and continue more studies focused on targeting the regulatory arm of the immune system to improve vaccines that are currently lacking.
Author contributions
All authors listed have contributed to the work and approved it for publication.
Funding
This work was supported by ANPCyT (Argentine National Agency for the Promotion of Science and Technology) (PICT 2018-01164 and PICT 2019-01948), CONICET (National Scientific and Technical Research Council) and the Universidad Nacional del Litoral, Argentina. CJ-C is supported by a Margarita Salas fellowship, granted by the University of Seville (Seville, Spain)
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Banchereau, J., Steinman, R. M. (1998). Dendritic cells and the control of immunity. Nature 392, 245–252. doi: 10.1038/32588
Batista-Duharte, A., Hassouneh, F., Alvarez-Heredia, P., Pera, A., Solana, R. (2022). Immune checkpoint inhibitors for vaccine improvements: current status and new approaches. Pharmaceutics 14 (8), 1721. doi: 10.3390/pharmaceutics14081721
Batista-Duharte, A., Téllez-Martínez, D., Fuentes, D. L. P., Carlos, I. Z. (2018). Molecular adjuvants that modulate regulatory T cell function in vaccination: a critical appraisal. Pharmacol. Res. 129, 237–250. doi: 10.1016/j.phrs.2017.11.026
Belkaid, Y. (2007). Regulatory T cells and infection: a dangerous necessity. Nat. Rev. Immunol. 7, 875–888. doi: 10.1038/nri2189
Cabrera, G., Marcipar, I. (2019). Vaccines and the regulatory arm of the immune system. an overview from the trypanosoma cruzi infection model. Vaccine 37, 3628–3637. doi: 10.1016/j.vaccine.2019.05.015
Chen, D. S., Mellman, I. (2013). Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–101–10. doi: 10.1016/j.immuni.2013.07.012
Del Prete, A., Salvi, V., Soriani, A., Laffranchi, M., Sozio, F., Bosisio, D., et al. (2023). Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol. Immunol 20 (5), 432–447 doi: 10.1038/s41423-023-00990-6
Fernández, A., Oliver, L., Alvarez, R., Fernández, L. E., Lee, K. P., Mesa, C. (2014). Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination. Hum. Vaccin Immunother. 10, 3251–3260. doi: 10.4161/hv.29847
Gabrilovich, D. I., Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162–174. doi: 10.1038/nri2506
Jiménez-Cortegana, C., Galassi, C., Klapp, V., Gabrilovich, D. I., Galluzzi, L. (2022). Myeloid-derived suppressor cells and radiotherapy. Cancer Immunol. Res. 10, 545–557. doi: 10.1158/2326-6066.CIR-21-1105
Jiménez-Cortegana, C., Palazón-Carrión, N., Martin Garcia-Sancho, A., Nogales-Fernandez, E., Carnicero-González, F., Ríos-Herranz, E., et al. (2021a). Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large b-cell lymphoma: translational results from the R2-GDP-GOTEL trial. J. Immunother. Cancer 9, e002323. doi: 10.1136/jitc-2020-002323
Jiménez-Cortegana, C., Sánchez-Martínez, P. M., Palazón-Carrión, N., Nogales-Fernández, E., Henao-Carrasco, F., Martín García-Sancho, A., et al. (2021b). Lower survival and increased circulating suppressor cells in patients with Relapsed/Refractory diffuse Large b-cell lymphoma with deficit of vitamin d levels using r-GDP plus lenalidomide (R2-GDP): results from the R2-GDP-GOTEL trial. Cancers (Basel) 13, 4622. doi: 10.3390/cancers13184622
Koinis, F., Xagara, A., Chantzara, E., Leontopoulou, V., Aidarinis, C., Kotsakis, A. (2021). Myeloid-derived suppressor cells in prostate cancer: present knowledge and future perspectives. Cells 11, 20. doi: 10.3390/cells11010020
Liu, Y.-F., Chen, Y.-Y., He, Y.-Y., Wang, J.-Y., Yang, J.-P., Zhong, S.-L., et al. (2017). Expansion and activation of granulocytic, myeloid-derived suppressor cells in childhood precursor b cell acute lymphoblastic leukemia. J. Leukoc. Biol. 102, 449–458. doi: 10.1189/jlb.5MA1116-453RR
Liu, J., Zhang, X., Cheng, Y., Cao, X. (2021). Dendritic cell migration in inflammation and immunity. Cell Mol. Immunol. 18, 2461–2471. doi: 10.1038/s41423-021-00726-4
Lu, X., Horner, J. W., Paul, E., Shang, X., Troncoso, P., Deng, P., et al. (2017). Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543, 728–732. doi: 10.1038/nature21676
Mabuchi, S., Sasano, T., Komura, N. (2021). Targeting myeloid-derived suppressor cells in ovarian cancer. Cells 10, 329. doi: 10.3390/cells10020329
Montes de Oca, M., Good, M. F., McCarthy, J. S., Engwerda, C. R. (2016). The impact of established immunoregulatory networks on vaccine efficacy and the development of immunity to malaria. J. Immunol. 197, 4518–4526. doi: 10.4049/jimmunol.1600619
Palazón-Carrión, N., Jiménez-Cortegana, C., Sánchez-León, M. L., Henao-Carrasco, F., Nogales-Fernández, E., Chiesa, M., et al. (2021). Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer. Sci. Rep. 11, 14426. doi: 10.1038/s41598-021-93838-w
Pawelec, G., Verschoor, C. P., Ostrand-Rosenberg, S. (2019). Myeloid-derived suppressor cells: not only in tumor immunity. Front. Immunol. 10, 1099. doi: 10.3389/fimmu.2019.01099
Plotkin, S. A. (2010). Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055–1065. doi: 10.1128/CVI.00131-10
Plotkin, S. A. (2018). Vaccines we need but don’t have. Viral Immunol. 31, 114–116. doi: 10.1089/vim.2017.0126
Sakaguchi, S., Mikami, N., Wing, J. B., Tanaka, A., Ichiyama, K., Ohkura, N. (2020). Regulatory T cells and human disease. Annu. Rev. Immunol. 38, 541–566. doi: 10.1146/annurev-immunol-042718-041717
Sakaguchi, S., Yamaguchi, T., Nomura, T., Ono, M. (2008). Regulatory T cells and immune tolerance. Cell 133, 775–787. doi: 10.1016/j.cell.2008.05.009
Sánchez-León, M. L., Jiménez-Cortegana, C., Silva Romeiro, S., Garnacho, C., de la Cruz-Merino, L., García-Domínguez, D. J., et al. (2023). Defining the emergence of new immunotherapy approaches in breast cancer: role of myeloid-derived suppressor cells. Int. J. Mol. Sci. 24, 5208. doi: 10.3390/ijms24065208
Sieminska, I., Baran, J. (2020). Myeloid-derived suppressor cells in colorectal cancer. Front. Immunol. 11. doi: 10.3389/fimmu.2020.01526
Keywords: vaccine, FOXP3+ regulatory T cells, myeloid-derived suppressor cells, cancer, pathogens, MDSCs, Tregs, vaccination
Citation: Jiménez-Cortegana C, Poveda C and Cabrera G (2023) Editorial: The regulatory immune system as a target to improve adjuvants and novel vaccines. Front. Cell. Infect. Microbiol. 13:1223689. doi: 10.3389/fcimb.2023.1223689
Received: 16 May 2023; Accepted: 30 May 2023;
Published: 05 June 2023.
Edited and Reviewed by:
Nahed Ismail, University of Illinois Chicago, United StatesCopyright © 2023 Jiménez-Cortegana, Poveda and Cabrera. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gabriel Cabrera, galt132000@gmail.com